Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases that is characterized by progressive memory loss and two main pathological hallmarks, including the extracellular amyloid plaques and intracellular neurofibrillary tangles. The microtubule-related protein tau is involved in the pathogenesis of many neurological diseases commonly known as tauopathies and is found to be abnormally hyperphosphorylated in AD and accumulated in neurons. Besides hyperphosphorylation, tau also undergoes abnormal glycosylation, ubiquitination, glycation, and other posttranslational modifications. These abnormalities lead to the aberrant aggregation of tau in the synaptic loci in AD. In this review, we highlighted the most recent studies about how tau is abnormally regulated and how those abnormalities play important roles in the pathogenesis of AD.
AndoK, Maruko-OtakeA, OhtakeY, HayashishitaM, SekiyaM, IijimaKM (2016) Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and Abeta42-induced tau toxicity. PLoS Genet12, e1005917.
2.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
3.
NobleW, PoolerAM, HangerDP (2011) Advances in tau-based drug discovery. Expert Opin Drug Discov6, 797–810.
4.
BertramL, LillCM, TanziRE (2010) The genetics of Alzheimer disease: Back to the future. Neuron68, 270–281.
5.
GiriM, ZhangM, LuY (2016) Genes associated with Alzheimer’s disease: An overview and current status. Clin Interv Aging11, 665–681.
6.
LeiP, AytonS, FinkelsteinDI, SpoerriL, CiccotostoGD, WrightDK, WongBX, AdlardPA, ChernyRA, LamLQ, RobertsBR, VolitakisI, EganGF, McLeanCA, CappaiR, DuceJA, BushAI (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med18, 291–295.
7.
LeiP, AytonS, AppukuttanAT, MoonS, DuceJA, Voli-takisI, ChernyR, WoodSJ, GreenoughM, BergerG, PantelisC, McGorryP, YungA, FinkelsteinDI, BushAI (2017) Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry22, 396–406.
8.
KosikKS (1990) Tau protein and Alzheimer’s disease. Curr Opin Cell Biol2, 101–104.
9.
TaiHC, Serrano-PozoA, HashimotoT, FroschMP, Spires-JonesTL, HymanBT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol181, 1426–1435.
10.
DottiC, BankerG, BinderL (1987) The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture. Neuroscience23, 121–130.
11.
GoedertM, SpillantiniM, JakesR, RutherfordD, CrowtherR (1989) Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron3, 519–526.
12.
IqbalK, LiuF, GongCX, Grundke-IqbalI (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res7, 656–664.
13.
HimmlerA, DrechselD, KirschnerMW, MartinDWJr (1989) Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol9, 1381–1388.
14.
BrandtR, HundeltM, ShahaniN (2005) Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim Biophys Acta1739, 331–354.
15.
AvilaJ, LucasJJ, PerezM, HernandezF (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev84, 361–384.
16.
TakanashiM, MoriH, ArimaK, MizunoY, HattoriN (2002) Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res104, 210–219.
17.
NeveRL, HarrisP, KosikKS, KurnitDM, DonlonTA (1986) Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res387, 271–280.
18.
GoedertM, SpillantiniMG, CrowtherRA (1992) Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. Proc Natl Acad Sci USA89, 1983–1987.
19.
GendronTF, PetrucelliL (2009) The role of tau in neurodegeneration. Mol Neurodegener4, 13.
20.
KolarovaM, Garcia-SierraF, BartosA, RicnyJ, RipovaD (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis2012, 731526.
21.
BrandtR, LeeG (1993) Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. J Biol Chem268, 3414–3419.
22.
BetrieAH, AytonS, BushAI, AngusJA, LeiP, WrightCE (2017) Evidence of a cardiovascular function for microtubule-associated protein tau. J Alzheimers Dis56, 849–860.
HaradaA, OguchiK, OkabeS, KunoJ, TeradaS, OhshimaT, Sato-YoshitakeR, TakeiY, NodaT, HirokawaN (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature369, 488–491.
25.
ClarkLN, PoorkajP, WszolekZ, GeschwindDH, Nasred-dineZS, MillerB, LiD, PayamiH, AwertF, MarkopoulouK, AndreadisA, D'SouzaI, LeeVM, ReedL, TrojanowskiJQ, ZhukarevaV, BirdT, SchellenbergG, WilhelmsenKC (1998) Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA95, 13103–13107.
26.
GoedertM, CrowtherRA, SpillantiniMG (1998) Tau mutations cause frontotemporal dementias. Neuron21, 955–958.
27.
HongM, ZhukarevaV, Vogelsberg-RagagliaV, WszolekZ, ReedL, MillerBI, GeschwindDH, BirdTD, McKeelD, GoateA (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science282, 1914–1917.
28.
HuttonM, LendonCL, RizzuP, BakerM, FroelichS, HouldenH, Pickering-BrownS, ChakravertyS, IsaacsA, GroverA (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature393, 702–705.
29.
Crespo-BielN, TheunisC, van LeuvenF (2012) Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer’s disease. Int J Alzheimers Dis2012, 251–426.
30.
SultanA, NesslanyF, VioletM, BegardS, LoyensA, Tala-hariS, MansurogluZ, MarzinD, SergeantN, HumezS, ColinM, BonnefoyE, BueeL, GalasMC (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem286, 4566–4575.
31.
WangY, MandelkowE (2016) Tau in physiology and pathology. Nat Rev Neurosci17, 5–21.
32.
GratuzeM, Joly-AmadoA, VieauD, BueeL, BlumD (2018) Mutual relationship between tau and central insulin signalling: Consequences for AD and tauopathies?Neuroendocrinology107, 181–195.
33.
CarrellRW, GooptuB (1998) Conformational changes and disease—serpins, prions and Alzheimer’s. Curr Opin Struct Biol8, 799–809.
34.
FoxN, HarveyRJ, RossorMN (1996) Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer’s disease. Rev Neurosci7, 21–28.
35.
HymanBT, AugustinackJC, IngelssonM (2005) Transcriptional and conformational changes of the tau molecule in Alzheimer’s disease. Biochim Biophys Acta1739, 150–157.
36.
GhoshalN, Garcia-SierraF, FuY, BeckettLA, MufsonEJ, KuretJ, BerryRW, BinderLI (2001) Tau-66: Evidence for a novel tau conformation in Alzheimer’s disease. J Neurochem77, 1372–1385.
37.
GhoshalN, Garcia-SierraF, WuuJ, LeurgansS, BennettDA, BerryRW, BinderLI (2002) Tau conformational changes correspond to impairments ofepisodic memory in mild cognitive impairment and Alzheimer’s disease. Exp Neurol177, 475–493.
38.
SotoC (1999) Alzheimer’s and prion disease as disorders of protein conformation: Implications for the design of novel therapeutic approaches. J Mol Med (Berl)77, 412–418.
39.
MartinL, LatypovaX, TerroF (2011) Post-translational modifications of tau protein: Implications for Alzheimer’s disease. Neurochem Int58, 458–471.
40.
Grundke-IqbalI, IqbalK, TungYC, QuinlanM, WisniewskiHM, BinderLI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA83, 4913–4917.
41.
ReynoldsMR, BerryRW, BinderLI (2005) Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: Implications for Alzheimer’s disease. Biochemistry44, 1690–1700.
42.
MinSW, ChoSH, ZhouY, SchroederS, HaroutunianV, SeeleyWW, HuangEJ, ShenY, MasliahE, MukherjeeC, MeyersD, ColePA, OttM, GanL (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron67, 953–966.
43.
van SwietenJ, SpillantiniMG (2007) Hereditary fron-totemporal dementia caused by Tau gene mutations. Brain Pathol17, 63–73.
44.
ZhouJ, YuQ, ZouT (2008) Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC Neurosci9(Suppl 2), S10.
45.
WolfeMS (2009) Tau mutations in neurodegenerative diseases. J Biol Chem284, 6021–6025.
46.
AlonsoAC, ZaidiT, Grundke-IqbalI, IqbalK (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA91,5562–5566.
47.
IqbalK, ZaidiT, BancherC, Grundke-IqbalI (1994) Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett349, 104–108.
48.
WangJZ, GongCX, ZaidiT, Grundke-IqbalI, IqbalK (1995) Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem270, 4854–4860.
49.
WangJZ, Grundke-IqbalI, IqbalK (1996) Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res Mol Brain Res38, 200–208.
50.
AlonsoAC, Grundke-IqbalI, IqbalK (1996) Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med2, 783–787.
51.
Mukaetova-LadinskaEB, HarringtonCR, RothM, WischikCM (1993) Biochemical and anatomical redistribution of tau protein in Alzheimer’s disease. Am J Pathol143, 565–578.
52.
HymanBT, Gomez-IslaT (1994) Alzheimer’s disease is a laminar, regional, and neural system specific disease, not a global brain disease. Neurobiol Aging15, 353–354; discussion 379-380.
53.
BuB, KlunemannH, SuzukiK, LiJ, BirdT, JinLW, VincentI (2002) Niemann-Pick disease type C yields possible clue for why cerebellar neurons do not form neurofibrillary tangles. Neurobiol Dis11, 285–297.
54.
PerezM, ArrasateM, Montejo De GarciniE, MunozV, AvilaJ (2001) In vitro assembly of tau protein: Mapping the regions involved in filament formation. Biochemistry40, 5983–5991.
55.
SimicG, Babic LekoM, WrayS, HarringtonC, DelalleI, Jovanov-MilosevicN, BazadonaD, BueeL, de SilvaR, Di GiovanniG, WischikC, HofPR (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules6, 6.
BraakH, AlafuzoffI, ArzbergerT, KretzschmarH, Del TrediciK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol112, 389–404.
58.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42, 631–639.
FosterNL, WilhelmsenK, SimaAA, JonesMZ, D'AmatoCJ, GilmanS (1997) Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference. Conference Participants. Ann Neurol41, 706–715.
61.
TolnayM, ProbstA (1999) REVIEW: Tau protein pathology in Alzheimer’s disease and related disorders. Neuropathol Appl Neurobiol25, 171–187.
62.
SpillantiniMG, MurrellJR, GoedertM, FarlowMR, KlugA, GhettiB (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA95, 7737–7741.
63.
PoorkajP, BirdTD, WijsmanE, NemensE, GarrutoRM, AndersonL, AndreadisA, WiederholtWC, RaskindM, SchellenbergGD (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol43, 815–825.
64.
HasegawaM, SmithMJ, GoedertM (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett437, 207–210.
65.
SpillantiniMG, CrowtherRA, GoedertM (1996) Comparison of the neurofibrillary pathology in Alzheimer’s disease and familial presenile dementia with tangles. Acta Neuropathol92, 42–48.
66.
KampersT, FriedhoffP, BiernatJ, MandelkowEM, MandelkowE (1996) RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett399, 344–349.
67.
KarA, KuoD, HeR, ZhouJ, WuJY (2005) Tau alternative splicing and frontotemporal dementia. Alzheimer Dis Assoc Disord19(Suppl 1), S29–36.
68.
GrabowskiPJ, BlackDL (2001) Alternative RNA splicing in the nervous system. Prog Neurobiol65, 289–308.
69.
MorrisM, KnudsenGM, MaedaS, TrinidadJC, IoanoviciuA, BurlingameAL, MuckeL (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci18, 1183–1189.
70.
GuJ, ChenF, IqbalK, GongCX, WangX, LiuF (2017) Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. J Biol Chem292, 10600–10612.
71.
GaoL, TuckerKL, AndreadisA (2005) Transcriptional regulation of the mouse microtubule-associated protein tau. Biochim Biophys Acta1681, 175–181.
72.
MiskaEA, Alvarez-SaavedraE, TownsendM, YoshiiA, SestanN, RakicP, Constantine-PatonM, HorvitzHR (2004) Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol5, R68.
73.
SempereLF, FreemantleS, Pitha-RoweI, MossE, DmitrovskyE, AmbrosV (2004) Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol5, R13.
74.
BaradO, MeiriE, AvnielA, AharonovR, BarzilaiA, Ben-twichI, EinavU, GiladS, HurbanP, KarovY, LobenhoferEK, SharonE, ShibolethYM, ShtutmanM, BentwichZ, EinatP (2004) MicroRNA expression detected by oligonucleotide microarrays: System establishment and expression profiling in human tissues. Genome Res14, 2486–2494.
75.
HohjohH, FukushimaT (2007) Expression profile analysis of microRNA (miRNA) in mouse central nervous system using a new miRNA detection system that examines hybridization signals at every step of washing. Gene391, 39–44.
76.
MehlerMF, MattickJS (2006) Non-coding RNAs in the nervous system. J Physiol575, 333–341.
77.
HebertSS, HorreK, NicolaiL, PapadopoulouAS, Man-demakersW, SilahtarogluAN, KauppinenS, DelacourteA, De StrooperB (2008) Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA105, 6415–6420.
78.
BoehmM, SlackF (2005) A developmental timing microRNA and its target regulate life span in C. elegans. Science310, 1954–1957.
PettegrewJW, WithersG, PanchalingamK, PostJF (1987) 31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer’s disease. J Neural Transm Suppl24, 261–268.
81.
AvilaJ, Santa-MariaI, PerezM, HernandezF, MorenoF (2006) Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol2006, 74539.
82.
DixitR, RossJL, GoldmanYE, HolzbaurEL (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science319, 1086–1089.
83.
CondeC, CaceresA (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci10, 319–332.
84.
IqbalK, LiuF, GongCX, Alonso AdelC, Grundke-IqbalI (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol118, 53–69.
85.
KhatoonS, Grundke-IqbalI, IqbalK (1994) Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett351, 80–84.
86.
LiB, ChohanMO, Grundke-IqbalI, IqbalK (2007) Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol113,501–511.
87.
KopkeE, TungYC, ShaikhS, AlonsoAC, IqbalK, Grundke-IqbalI (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem268, 24374–24384.
88.
StoreyKB (2003) Mammalian hibernation. Transcriptional and translational controls. Adv Exp Med Biol543, 21–38.
89.
StielerJT, BullmannT, KohlF, ToienO, BrucknerMK, HartigW, BarnesBM, ArendtT (2011) The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation. PLoS One6, e14530.
90.
HartigW, StielerJ, BoeremaAS, WolfJ, SchmidtU, WeissfussJ, BullmannT, StrijkstraAM, ArendtT (2007) Hibernation model of tau phosphorylation in hamsters: Selective vulnerability of cholinergic basal forebrain neurons - implications for Alzheimer’s disease. Eur J Neurosci25, 69–80.
91.
ArendtT, StielerJ, StrijkstraAM, HutRA, RudigerJ, Van der ZeeEA, HarkanyT, HolzerM, HartigW (2003) Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci23, 6972–6981.
92.
AlexandrovPN, DuaP, HillJM, BhattacharjeeS, ZhaoY, LukiwWJ (2012) microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol3, 365–373.
93.
AbsalonS, KochanekDM, RaghavanV, KrichevskyAM (2013) MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci33, 14645–14659.
94.
CogswellJP, WardJ, TaylorIA, WatersM, ShiY, CannonB, KelnarK, KemppainenJ, BrownD, ChenC, PrinjhaRK, RichardsonJC, SaundersAM, RosesAD, RichardsCA (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis14, 27–41.
95.
DorvalV, NelsonPT, HebertSS (2013) Circulating microRNAs in Alzheimer’s disease: The search for novel biomarkers. Front Mol Neurosci6, 24.
96.
LauP, BossersK, JankyR, SaltaE, FrigerioCS, BarbashS, RothmanR, SierksmaAS, ThathiahA, GreenbergD, PapadopoulouAS, AchselT, AyoubiT, SoreqH, Verhaa-genJ, SwaabDF, AertsS, De StrooperB (2013) Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med5, 1613–1634.
97.
AbeM, BoniniNM (2013) MicroRNAs and neurodegeneration: Role and impact. Trends Cell Biol23, 30–36.
98.
HebertSS, De StrooperB (2009) Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci32, 199–206.
99.
HernandezF, LucasJJ, CuadrosR, AvilaJ (2003) GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging24, 1087–1094.
100.
Gordon-KrajcerW, YangL, Ksiezak-RedingH (2000) Conformation of paired helical filaments blocks dephosphorylation of epitopes shared with fetal tau except Ser199/202 and Ser202/Thr205. Brain Res856, 163–175.
101.
AlonsoA, ZaidiT, NovakM, Grundke-IqbalI, IqbalK (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA98, 6923–6928.
102.
HangerDP, GibbGM, De SilvaR, BoutajangoutA, BrionJP, ReveszT, LeesAJ, AndertonBH (2002) The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett531, 538–542.
103.
LovestoneS, ReynoldsCH (1997) The phosphorylation of tau: A critical stage in neurodevelopment and neurode-generative processes. Neuroscience78, 309–324.
104.
SergeantN, BussiereT, VermerschP, LejeuneJP, Dela-courteA (1995) Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. Neuroreport6, 2217–2220.
105.
Mietelska-PorowskaA, WasikU, GorasM, FilipekA, NiewiadomskaG (2014) Tau protein modifications and interactions: Their role in function and dysfunction. Int J Mol Sci15, 4671–4713.
106.
Schedin-WeissS, WinbladB, TjernbergLO (2014) The role of protein glycosylation in Alzheimer disease. FEBS J281, 46–62.
107.
SatoY, NaitoY, Grundke-IqbalI, IqbalK, EndoT (2001) Analysis of N-glycans of pathological tau: Possible occurrence of aberrant processing of tau in Alzheimer’s diseas. FEBS Lett496, 152–160.
108.
LiuF, ZaidiT, IqbalK, Grundke-IqbalI, MerkleRK, GongCX (2002) Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS Lett512, 101–106.
109.
LefebvreT, FerreiraS, Dupont-WalloisL, BussiereT, DupireMJ, DelacourteA, MichalskiJC, Caillet-BoudinML (2003) Evidence of a balance between phosphoryla-tion and O-GlcNAc glycosylation of Tau proteins-a role in nuclear localization. Biochim Biophys Acta1619, 167–176.
110.
GongCX, LiuF, IqbalK (2016) O-GlcNAcylation: A regulator of tau pathology and neurodegeneration. Alzheimers Dement12, 1078–1089.
111.
LiuF, ZaidiT, IqbalK, Grundke-IqbalI, GongCX (2002) Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience115, 829–837.
112.
LiuF, IqbalK, Grundke-IqbalI, GongCX (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett530, 209–214.
113.
HershkoA, CiechanoverA (1998) The ubiquitin system. Annu Rev Biochem67, 425–479.
114.
MoriH, KondoJ, IharaY (1987) Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science235, 1641–1644.
115.
BueeL, BussiereT, Buee-ScherrerV, DelacourteA, HofPR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev33, 95–130.
116.
Morishima-KawashimaM, HasegawaM, TakioK, SuzukiM, TitaniK, IharaY (1993) Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron10, 1151–1160.
117.
EbleAS, ThorpeSR, BaynesJW (1983) Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem258, 9406–9412.
118.
LedesmaMD, BonayP, ColacoC, AvilaJ (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem269, 21614–21619.
119.
LedesmaMD, BonayP, AvilaJ (1995) Tau protein from Alzheimer’s disease patients is glycated at its tubulin-binding domain. J Neurochem65, 1658–1664.
SchweersO, MandelkowEM, BiernatJ, MandelkowE (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci USA92, 8463–8467.
Haj-YahyaM, LashuelHA (2018) Protein semisyn-thesis provides access to tau disease-associated post-translational modifications (PTMs) and paves the way to deciphering the tau PTM code in health and diseased states. J Am Chem Soc140, 6611–6621.
125.
Alavi NainiSM, Soussi-YanicostasN (2015) Tau hyper-phosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?Oxid Med Cell Longev2015, 151979.
126.
CohenTJ, GuoJL, HurtadoDE, KwongLK, MillsIP, TrojanowskiJQ, LeeVM (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun2, 252.
127.
IrwinDJ, CohenTJ, GrossmanM, ArnoldSE, XieSX, LeeVM, TrojanowskiJQ (2012) Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain135, 807–818.
128.
Lucke-WoldB, SeidelK, UdoR, OmaluB, OrnsteinM, NolanR, RosenC, RossJ (2017) Role of tau acetylation in Alzheimer’s disease and chronic traumatic encephalopa-thy: The way forward for successful treatment. J Neurol Neurosurg4, 140.
129.
TrzeciakiewiczH, TsengJH, WanderCM, MaddenV, Tri-pathyA, YuanCX, CohenTJ (2017) A dual pathogenic mechanism links tau acetylation to sporadic tauopathy. Sci Rep7, 44102.
130.
PanzaF, SolfrizziV, SeripaD, ImbimboBP, LozuponeM, SantamatoA, ZeccaC, BarulliMR, BellomoA, PilottoA, DanieleA, GrecoA, LogroscinoG (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int2016, 3245935.
SohnPD, TracyTE, SonHI, ZhouY, LeiteRE, MillerBL, SeeleyWW, GrinbergLT, GanL (2016) Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol Neurodegener11, 47.
133.
MinSW, ChenX, TracyTE, LiY, ZhouY, WangC, Shi-rakawaK, MinamiSS, DefensorE, MokSA, SohnPD, SchillingB, CongX, EllerbyL, GibsonBW, JohnsonJ, KroganN, ShamlooM, GestwickiJ, MasliahE, VerdinE, GanL (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med21, 1154–1162.
134.
Lasagna-ReevesCA, Castillo-CarranzaDL, SenguptaU, SarmientoJ, TroncosoJ, JacksonGR, KayedR (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J26, 1946–1959.
135.
MaedaS, SaharaN, SaitoY, MurayamaS, IkaiA, TakashimaA (2006) Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer’s disease. Neurosci Res54, 197–201.
136.
TracyTE, GanL (2017) Acetylated tau in Alzheimer’s disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy. Bioessays39. doi:10.1002/bies.201600224
137.
DerisbourgM, LeghayC, ChiappettaG, Fernandez-GomezFJ, LaurentC, DemeyerD, CarrierS, Buee-ScherrerV, BlumD, VinhJ, SergeantN, VerdierY, BueeL, HamdaneM (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep5, 9659.
138.
FasuloL, UgoliniG, VisintinM, BradburyA, BrancoliniC, VerzilloV, NovakM, CattaneoA (2000) The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem75, 624–633.
139.
Matthews-RobersonTA, QuintanillaRA, DingH, JohnsonGV (2008) Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticu-lum stress induced cell death. Brain Res1234, 206–212.
PaholikovaK, SalingovaB, OpattovaA, SkrabanaR, MajerovaP, ZilkaN, KovacechB, ZilkovaM, BarathP, NovakM (2015) N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J Alzheimers Dis43, 915–926.
144.
PerryG, FriedmanR, ShawG, ChauV (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A84, 3033–3036.
145.
WischikCM, SchelterBO, WischikDJ, StoreyJMD, HarringtonCR (2018) Modeling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development. J Alzheimers Dis62, 1287–1303.
146.
UgoliniG, CattaneoA, NovakM (1997) Co-localization of truncated tau and DNA fragmentation in Alzheimer’s disease neurones. Neuroreport8, 3709–3712.
147.
Basurto-IslasG, Luna-MunozJ, Guillozet-BongaartsAL, BinderLI, MenaR, Garcia-SierraF (2008) Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol67, 470–483.
148.
HorowitzPM, PattersonKR, Guillozet-BongaartsAL, ReynoldsMR, CarrollCA, WeintraubST, BennettDA, CrynsVL, BerryRW, BinderLI (2004) Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer’s disease. J Neurosci24, 7895–7902.
149.
ChungCW, SongYH, KimIK, YoonWJ, RyuBR, JoDG, WooHN, KwonYK, KimHH, GwagBJ, Mook-JungIH, JungYK (2001) Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis8, 162–172.
150.
FasuloL, UgoliniG, CattaneoA (2005) Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J Alzheimers Dis7, 3–13.
151.
Garcia-SierraF, Mondragon-RodriguezS, Basurto-IslasG (2008) Truncation of tau protein and its pathological significance in Alzheimer’s disease. J Alzheimers Dis14, 401–409.
152.
RissmanRA, PoonWW, Blurton-JonesM, OddoS, TorpR, VitekMP, LaFerlaFM, RohnTT, CotmanCW (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest114, 121–130.
153.
CanuN, DusL, BarbatoC, CiottiMT, BrancoliniC, RinaldiAM, NovakM, CattaneoA, BradburyA, CalissanoP (1998) Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci18, 7061–7074.
154.
ParkSY, FerreiraA (2005) The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci25, 5365–5375.
155.
RamettiA, EsclaireF, YardinC, TerroF (2004) Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem279, 54518–54528.
156.
SaitoM, ChakrabortyG, MaoRF, PaikSM, VadaszC, SaitoM (2010) Tau phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing mouse brain. Neurochem Res35, 651–659.
157.
Mondragon-RodriguezS, Basurto-IslasG, Santa-MariaI, MenaR, BinderLI, AvilaJ, SmithMA, PerryG, Garcia-SierraF (2008) Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer’s disease. Int J Exp Pathol89, 81–90.
158.
WatanabeT, IharaN, ItohT, FujitaT, SugimotoY (2000) Deletion mutation in Drosophila ma-l homologous, putative molybdopterin cofactor sulfurase gene is associated with bovine xanthinuria type II. J Biol Chem275, 21789–21792.
159.
IqbalK, Alonso AdelC, ChenS, ChohanMO, El-AkkadE, GongCX, KhatoonS, LiB, LiuF, RahmanA, TanimukaiH, Grundke-IqbalI (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta1739, 198–210.
HoriguchiT, UryuK, GiassonBI, IschiropoulosH, Light-FootR, BellmannC, Richter-LandsbergC, LeeVM, TrojanowskiJQ (2003) Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol163, 1021–1031.
162.
CappellettiG, TedeschiG, MaggioniMG, NegriA, NonnisS, MaciR (2004) The nitration of tau protein in neurone-like PC12 cells. FEBS Lett562, 35–39.
163.
ReynoldsMR, ReyesJF, FuY, BigioEH, Guillozet-BongaartsAL, BerryRW, BinderLI (2006) Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J Neurosci26, 10636–10645.
164.
WangDS, DicksonDW, MalterJS (2008) Tissue transglutaminase, protein cross-linking and Alzheimer’s disease: Review and views. Int J Clin Exp Pathol1, 5–18.
165.
De CalignonA, PolydoroM, Suarez-CalvetM, WilliamC, AdamowiczDH, KopeikinaKJ, PitstickR, SaharaN, AsheKH, CarlsonGA, Spires-JonesTL, HymanBT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron73, 685–697.
166.
FrostB, JacksRL, DiamondMI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem284, 12845–12852.
167.
ClavagueraF, BolmontT, CrowtherRA, AbramowskiD, FrankS, ProbstA, FraserG, StalderAK, BeibelM, StaufenbielM, JuckerM, GoedertM, TolnayM (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol11, 909–913.
168.
PlanelE, BrettevilleA, LiuL, ViragL, DuAL, YuWH, DicksonDW, WhittingtonRA, DuffKE (2009) Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J23, 2595–2604.
169.
BrelstaffJ, TolkovskyAM, GhettiB, GoedertM, SpillantiniMG (2018) Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep24, 1939–1948.e1934.
170.
RubenGC, IqbalK, Grundke-IqbalI, WisniewskiHM, CiardelliTL, JohnsonJEJr (1991) The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer. J Biol Chem266, 22019–22027.
171.
ArrasateM, PerezM, Armas-PortelaR, AvilaJ (1999) Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett446, 199–202.
172.
GamblinTC, BerryRW, BinderLI (2003) Tau polymerization: Role of the amino terminus. Biochemistry42, 2252–2257.
173.
KuretJ, ChiritaCN, CongdonEE, KannanayakalT, LiG, NeculaM, YinH, ZhongQ (2005) Pathways of tau fibrillization. Biochim Biophys Acta1739, 167–178.
174.
KingME, GamblinTC, KuretJ, BinderLI (2000) Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem74, 1749–1757.
175.
PattersonKR, RemmersC, FuY, BrookerS, KanaanNM, VanaL, WardS, ReyesJF, PhilibertK, GlucksmanMJ, BinderLI (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem286, 23063–23076.
176.
SantacruzK, LewisJ, SpiresT, PaulsonJ, KotilinekL, IngelssonM, GuimaraesA, DeTureM, RamsdenM, McGowanE, ForsterC, YueM, OrneJ, JanusC, Mari-ashA, KuskowskiM, HymanB, HuttonM, AsheKH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science309, 476–481.
177.
SydowA, Van der JeugdA, ZhengF, AhmedT, BalschunD, PetrovaO, DrexlerD, ZhouL, RuneG, MandelkowE, D'HoogeR, AlzheimerC, MandelkowEM (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci31, 2511–2525.
178.
BergerZ, RoderH, HannaA, CarlsonA, RangachariV, YueM, WszolekZ, AsheK, KnightJ, DicksonD, AndorferC, RosenberryTL, LewisJ, HuttonM, JanusC (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci27, 3650–3662.
179.
BulicB, PickhardtM, SchmidtB, MandelkowEM, WaldmannH, MandelkowE (2009) Development of tau aggregation inhibitors for Alzheimer’s disease. Angew Chem Int Ed Engl48, 1740–1752.
180.
von BergenM, FriedhoffP, BiernatJ, HeberleJ, MandelkowEM, MandelkowE (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA97, 5129–5134.
181.
SchneiderA, BiernatJ, von BergenM, MandelkowE, MandelkowEM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry38, 3549–3558.
182.
BarghornS, DaviesP, MandelkowE (2004) Tau paired helical filaments from Alzheimer’s disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry43, 1694–1703.
183.
LarbigG, PickhardtM, LloydDG, SchmidtB, MandelkowE (2007) Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: A ligand based approach results in successful scaffold hopping. Curr Alzheimer Res4, 315–323.
184.
CongdonEE, DuffKE (2008) Is tau aggregation toxic or protective?J Alzheimers Dis14, 453–457.
185.
CroweA, HuangW, BallatoreC, JohnsonRL, HoganAM, HuangR, WichtermanJ, McCoyJ, HurynD, AuldDS, SmithAB, 3rd, IngleseJ, TrojanowskiJQ, AustinCP, BrundenKR, LeeVM (2009) Identification of aminoth-ienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry48, 7732–7745.
186.
CroweA, BallatoreC, HydeE, TrojanowskiJQ, LeeVM (2007) High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun358, 1–6.
187.
PickhardtM, von BergenM, GazovaZ, HascherA, BiernatJ, MandelkowEM, MandelkowE (2005) Screening for inhibitors of tau polymerization. Curr Alzheimer Res2, 219–226.
188.
TaniguchiS, SuzukiN, MasudaM, HisanagaS, Iwat-suboT, GoedertM, HasegawaM (2005) Inhibition of heparin-induced tau filament formation by phenoth-iazines, polyphenols, and porphyrins. J Biol Chem280, 7614–7623.
189.
ImHI, KennyPJ (2012) MicroRNAs in neuronal function and dysfunction. Trends Neurosci35, 325–334.
190.
FemminellaGD, FerraraN, RengoG (2015) The emerging role of microRNAs in Alzheimer’s disease. Front Physiol6, 40.
191.
HebertSS, SergeantN, BueeL (2012) MicroRNAs and the regulation of tau metabolism. Int J Alzheimers Dis2012, 406561.
192.
HebertSS, PapadopoulouAS, SmithP, GalasMC, PlanelE, SilahtarogluAN, SergeantN, BueeL, De StrooperB (2010) Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet19, 3959–3969.
193.
YasojimaK, McGeerEG, McGeerPL (1999) Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA. Brain Res831, 301–305.
194.
CaffreyTM, JoachimC, ParacchiniS, EsiriMM, WadeMartinsR (2006) Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet15, 3529–3537.
195.
LeiP, AytonS, MoonS, ZhangQ, VolitakisI, FinkelsteinDI, BushAI (2014) Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener9, 29.
196.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
197.
ZhouL, McInnesJ, WierdaK, HoltM, HerrmannAG, JacksonRJ, WangYC, SwertsJ, BeyensJ, MiskiewiczK, VilainS, DewachterI, MoecharsD, De StrooperB, Spires-JonesTL, De WitJ, VerstrekenP (2017) Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun8, 15295.
198.
LaFerlaFM, OddoS (2005) Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med11, 170–176.
199.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Aß and synaptic dysfunction. Neuron39, 409–421.
McLellanME, KajdaszST, HymanBT, BacskaiBJ (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci23, 2212–2217.
202.
Guerrero-MunozMJ, GersonJ, Castillo-CarranzaDL (2015) Tau oligomers: The toxic player at synapses in Alzheimer’s disease. Front Cell Neurosci9, 464.
203.
Meyer-LuehmannM, Spires-JonesTL, PradaC, Garcia-AllozaM, De CalignonA, RozkalneA, Koenigsknecht-TalbooJ, HoltzmanDM, BacskaiBJ, HymanBT (2008) Rapid appearance and local toxicity of amyloid-ß plaques in a mouse model of Alzheimer’s disease. Nature451, 720–724.
JankowskyJL, XuG, FromholtD, GonzalesV, BorcheltDR (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol62, 1220–1227.
206.
WoodhouseA, WestAK, ChuckowreeJA, VickersJC, DicksonTC (2005) Does beta-amyloid plaque formation cause structural injury to neuronal processes?Neurotox Res7, 5–15.
207.
SpillantiniMG, GoedertM (2013) Tau pathology and neurodegeneration. Lancet Neurol12, 609–622.
208.
MahVH, EskinTA, KazeeAM, LaphamL, HigginsGA (1992) In situ hybridization of calcium/calmodulin dependent protein kinase II and tau mRNAs; species differences and relative preservation in Alzheimer’s disease. Brain Res Mol Brain Res12, 85–94.
209.
PoppekD, KeckS, ErmakG, JungT, StolzingA, UllrichO, DaviesKJ, GruneT (2006) Phosphorylation inhibits turnover of the tau protein by the proteasome: Influence of RCAN1 and oxidative stress. Biochem J400, 511–520.
210.
YangLS, Ksiezak-RedingH (1995) Calpain-induced pro-teolysis of normal human tau and tau associated with paired helical filaments. FEBS J233, 9–17.
211.
LiuYH, WeiW, YinJ, LiuGP, WangQ, CaoFY, WangJZ (2009) Proteasome inhibition increases tau accumulation independent of phosphorylation. Neurobiol Aging30, 1949–1961.
